Company ContraVir Pharmaceuticals Inc OTC Bulletin Board
Equities
US21234W1036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
05-21 | Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-22 | Sector Update: Health Care Stocks Increase Late Afternoon | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 15-12-31 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-02 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Daniel Trepanier
PRN | Corporate Officer/Principal | - | 19-10-02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 13-05-14 |
Timothy Block
BRD | Director/Board Member | 69 | 13-11-25 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 22-06-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,688 | 0 | 0 | 94.28 % |
Stock B | 1 | 5,799,126 | 5,467,205 ( 94.28 %) | 0 | |
Stock C | 0 | 85,581 | 0 | 0 |
Company contact information
Hepion Pharmaceuticals, Inc.
399 Thornall Street 1st Floor
08837, Edison
+732 902 4000
http://www.hepionpharma.com![address ContraVir Pharmaceuticals Inc](https://cdn.zonebourse.com/static/address/15749842.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+24.05% | 27.87B | |
-17.74% | 20.95B | |
-15.08% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- HEPA Stock
- Stock
- Company ContraVir Pharmaceuticals Inc